002349

6.781.02%

"Performance" Novartis' net profit fell 15% last quarter, expects core operating profit to decline for the first time in six years this year

One of Switzerland's two major pharmaceutical giants, NOVARTIS AG, stated that its best-selling heart disease drug Entresto and other products are facing further pressure from generics. It is expected that core operating profit, calculated at constant exchange rates, will decline by a low single-digit percentage this year, marking the first decline in at least six years, whereas the market had originally expected growth.

NOVARTIS AG's revenue in the fourth quarter of last year grew by 1% to USD 13.336 billion, while profit fell by 15% to USD 2.404 billion

Source: AASTOCKS The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.